The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Projects Update

29 Sep 2008 07:00

RNS Number : 5036E
ViaLogy PLC
29 September 2008
 



ViaLogy Plc ("ViaLogy" or "the Company")

Projects Update

Pasadena, California - 29 September, 2008Vialogy PLC (AIM: VIY), the AiM-listed technology company, is pleased to announce significant developments in three of its major projects. 

Software installation in military base

The Company has been awarded a sub-contract from a major US defense system integrator for the insertion of ViaLogy's sensor interoperability platform software into an operating military base security system. ViaLogy will integrate the multiple perimeter surveillance systems on the base, simplifying operations and eliminating system failure in security deployment. 

More detailed information on the project and the names of the systems integrator firm and the specific military base cannot be disclosed for national security reasons.

In addition, SPM® was recently deployed by Los Angeles County first responders at a major sports event attended by over 90,000 fans to demonstrate and assess effectiveness in providing advance warning and crisis management in the event of a chemical or biological terrorist event. Following this success, LA County also deployed SPM to co-ordinate security and surveillance at the 60th Emmy Awards ceremony in Los Angeles. 

"The diversity of these SPM applications helps to position the product as the certified CBRNE (Chemical, Biological, Radiological, Nuclear and Explosive detection) and physical security sensor integration engine for purchases of enterprise-grade systems. We anticipate future customers will include state, local and federal procurement agencies, including the Department of Homeland Security, and system integrator firms", said Terry Bond, ViaLogy's Chairman.

New dates set for Oil & Gas validation

Hurricane Ike has caused a brief postponement of the ViaLogy-Atascosa Engineering partnership plans to drill its first well and thereby prove the value of ViaLogy's Quantum Resonance Interferometry (QRI™) technology which is being used to determine the oil reservoir's location, capacity and porosity, as well as the exact drill site. This adaptation of QRI is branded QuantumRD.

"Ike's unpredictable progress through Texas meant we had to delay preparations for erecting the drilling equipment", said Mr. Bond. "At one point it appeared that the site, near San Antonio, would be in the eye of the storm. Fortunately it transpired the area was on the perimeter and we sustained minimal damage."

While the project is a pilot, this is a fully operational extraction site and a strike should substantiate the effectiveness of the technology in the oil discovery process. Drilling is now scheduled for mid-October and results will be available towards the end of that month.

Aerial pipeline surveys in October

The second imminent application for QRI, called QSUB™, will be used to determine exact geolocation and condition of underground oil and gas pipelines. Proof-of-concept flights by Sky Research Inc of Ashland, Oregon, www.skyresearch.com, organised by ViaLogy and its partner firm ASTFS, are scheduled for this October. The aim is for QSUB technology to analyse data from airborne synthetic aperture radar (SAR) and light detection and ranging (LIDAR) sensors. ViaLogy has received strong indications of interest from leading pipeline firms in the success of the proof-of-concept work and in purchase of the operational service when available.

"There are almost 3 million kilometres of buried pipeline in the US alone", said Mr. Bond. "A cost-effective means of providing exact pipeline location and status is in high demand by both pipeline firms and regulatory agencies. We believe that the latest radar equipment, combined with QSUB data analysis will enable this to be done by aerial surveys."

Ends

Further information from:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

Stockbroker - St. Helen's Capital PLC +44 (0) 20-7628 5582 

PR Consultants - Redleaf Communications 

Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESBRGDCLDDGGII
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.